Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s stock price hit a new 52-week high on Wednesday . The company traded as high as C$5.15 and last traded at C$5.15, with a volume of 2788 shares traded. The stock had previously closed at C$0.17.
Aptose Biosciences Stock Performance
The company has a debt-to-equity ratio of -117.37, a current ratio of 1.05 and a quick ratio of 5.41. The company has a fifty day moving average of C$0.29 and a 200 day moving average of C$0.42. The stock has a market cap of C$221.75 million, a P/E ratio of -1.03 and a beta of 1.36.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- What is the Nasdaq? Complete Overview with History
- Buffett’s on the Sidelines – Should You Follow?
- Best Aerospace Stocks Investing
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
